Literature DB >> 10997926

EP(1) and EP(4) receptors mediate prostaglandin E(2) actions in the microcirculation of rat kidney.

K E Purdy1, W J Arendshorst.   

Abstract

Vasodilator prostaglandin PGE(2) protects the kidney from excessive vasoconstriction during contraction of extracellular fluid volume and pathophysiological states. However, it is not yet clear which of the four known E-prostanoid (EP) receptors is localized to resistance vessels and mediates net vasodilation. In the present study, we assessed the presence, signal transduction, and actions of EP receptor subtypes in preglomerular arterioles of Sprague-Dawley rat kidneys. RNA encoding EP(1), an EP(1)-variant, and EP(4) receptors was identified by RT-PCR in freshly isolated preglomerular microvessels; cultured preglomerular vascular smooth muscle cells (VSMC) had EP(1)-variant and EP(4) RNA but lacked EP(1). EP(2) and EP(3) receptors were undetectable in both vascular preparations. In studies of cell signaling, stimulation of cAMP by various receptor agonists is consistent with primary actions of PGE(2) on the EP(4) receptor, with no inhibition of cAMP by EP(1) receptors. Studies of cytosolic calcium concentration in cultured renal VSMC support an inhibitory role of EP(4) during ANG II stimulation. In vivo renal blood flow (RBF) studies indicate that the EP(4) receptor is the primary receptor mediating sustained renal vasodilation produced by PGE(2), whereas the EP(1) receptor elicits transient vasoconstriction. The EP(1)-variant receptor does not appear to possess any cAMP or cytosolic calcium signaling capable of affecting RBF. Collectively, these studies demonstrate that the EP(4) receptor is the major receptor in preglomerular VSMC. EP(4) mediates PGE(2)-induced vasodilation in the rat kidney and signals through G(s) proteins to stimulate cAMP and inhibit cytosolic calcium concentration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997926     DOI: 10.1152/ajprenal.2000.279.4.F755

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  19 in total

Review 1.  PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.

Authors:  Rania Nasrallah; Ramzi Hassouneh; Richard L Hébert
Journal:  J Am Soc Nephrol       Date:  2015-08-28       Impact factor: 10.121

2.  Furosemide-induced renal medullary hypoperfusion in the rat: role of tissue tonicity, prostaglandins and angiotensin II.

Authors:  Leszek Dobrowolski; Janusz Sadowski
Journal:  J Physiol       Date:  2005-06-16       Impact factor: 5.182

3.  Regulation of 3',5'-cAMP in preglomerular smooth muscle and endothelial cells from genetically hypertensive rats.

Authors:  Dongmei Cheng; Jin Ren; Delbert G Gillespie; Zaichuan Mi; Edwin K Jackson
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

Review 4.  Heme Oxygenases in Cardiovascular Health and Disease.

Authors:  Anita Ayer; Abolfazl Zarjou; Anupam Agarwal; Roland Stocker
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

5.  Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats.

Authors:  Kazuhiko Mizukami; Hiroyuki Yoshida; Eisuke Nozawa; Koichi Wada; Tohru Ugawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-12-15       Impact factor: 3.000

6.  Berberine regulates the expression of E-prostanoid receptors in diabetic rats with nephropathy.

Authors:  Li Qin Tang; Sheng Liu; Shan Tang Zhang; Ling Na Zhu; Feng Ling Wang
Journal:  Mol Biol Rep       Date:  2014-02-01       Impact factor: 2.316

7.  Pharmacological properties of ASP7657, a novel, potent, and selective prostaglandin EP4 receptor antagonist.

Authors:  Kazuhiko Mizukami; Hiroaki Kamada; Hiroyuki Yoshida; Ikuko Ishii; Eisuke Nozawa; Koichi Wada; Tohru Ugawa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-03       Impact factor: 3.000

Review 8.  Cellular mediators of renal vascular dysfunction in hypertension.

Authors:  Bharathy Ponnuchamy; Raouf A Khalil
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-02-18       Impact factor: 3.619

9.  International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1-4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions.

Authors:  Xavier Norel; Yukihiko Sugimoto; Gulsev Ozen; Heba Abdelazeem; Yasmine Amgoud; Amel Bouhadoun; Wesam Bassiouni; Marie Goepp; Salma Mani; Hasanga D Manikpurage; Amira Senbel; Dan Longrois; Akos Heinemann; Chengcan Yao; Lucie H Clapp
Journal:  Pharmacol Rev       Date:  2020-10       Impact factor: 25.468

10.  Antagonism of the prostaglandin E2 EP1 receptor in MDCK cells increases growth through activation of Akt and the epidermal growth factor receptor.

Authors:  Mary Taub; Robert Parker; Paremala Mathivanan; Muhamad Asnawi Mohd Ariff; Trina Rudra
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.